Kendra Coonse, MD
Interventional Cardiology · Boise, IDNPI 1699181214
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (53.3%), food and beverage and grants — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Abbott at 29.6% of the total. Reporting peaked in 2023 at $5,624 and has fallen 95.5% since, to $252 in 2025.
Across 225 payments — averaging $73.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Medtronic$3K
- Abiomed$3K
- Penumbra, Inc.$3K
- Boston Scientific$2K
- Novartis$444
- plus $776 from 13 others
What the payments were for
- Grants$1,2458%
- Travel & lodging$8,79953%
- Food & beverage$6,43639%
- Education$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 85 | $4,897 |
| Medtronic(2 entities) | 35 | $3,387 |
| Abiomed | 17 | $2,908 |
| Penumbra, Inc. | 13 | $2,570 |
| Boston Scientific | 14 | $1,536 |
| Novartis | 41 | $444 |
| Inari Medical, Inc. | 2 | $225 |
| Heartflow, Inc. | 3 | $143 |
| Shockwave Medical, Inc | 3 | $124 |
| Cvrx, Inc. | 1 | $87 |
| Johnson & Johnson | 2 | $35 |
| AstraZeneca | 2 | $35 |
| Acist Medical Systems, Inc. | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Livanova USA, Inc. | 1 | $20 |
| Pfizer | 1 | $16 |
| Teleflex LLC | 1 | $16 |
| Edwards Lifesciences | 1 | $15 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$2,437
- Indigo System$2,053
- ASSURITY$1,828
- OPTIS$1,203
- GENERAL - STRUCTURAL$1,105
- Resolute$442
- CoreValve Evolut$288
- ADVISA DR MRI SURESCAN$284
- Penumbra System$278
- FLOWTRIEVER CATHETER, S$152
- CT THROMBECTOMY SYSTEM KIT$152
- MitraClip$126
- FFRct$105
How this compares
$16,518 in reported general payments places this provider in the 85th percentile of 29 interventional cardiology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 112 | $102,215 |
| FarxigaDapagliflozin Propanediol | 73 | $43,750 |
| XareltoRivaroxaban | 22 | $21,679 |
| EntrestoSacubitril/Valsartan | 19 | $20,896 |
| Metoprolol Succinate | 144 | $2,286 |
| Atorvastatin Calcium | 197 | $1,716 |
| Flecainide Acetate | 31 | $1,379 |
| Ezetimibe | 46 | $918 |
| ClopidogrelClopidogrel Bisulfate | 70 | $832 |
| Potassium Chloride | 24 | $786 |
| Omeprazole | 47 | $518 |
| Pravastatin Sodium | 18 | $377 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 36 | $302 |
| Losartan Potassium | 35 | $290 |
| Spironolactone | 31 | $246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $16 | $102,215112 claims |
| AstraZenecaFarxiga | $35 | $43,75073 claims |
| Johnson & JohnsonXarelto | $35 | $21,67922 claims |
| NovartisEntresto | $444 | $20,89619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 29 interventional cardiology providers in Idaho.
Other interventional cardiology in Boise
- Joseph WalshBoise$115K
- Kara DenbyBoise$18K
- Jeffrey HeslopBoise$17K
- Patrick ColemanBoise$11K
- Robert DuerrBoise$11K
- Frederick CostelloBoise$5K
- Alex JohnsonBoise$3K
- David CoyleBoise$3K
- Mark ParentBoise$2K
- Carl KapadiaBoise$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.